USP29 and hepatocellular carcinoma: The findings highlight USP29 and HIF1α as biomarkers for Sorafenib resistance in HCC and the USP29-HIF1α-glycolysis regulatory cascade as a potential therapeutic target to overcome Sorafenib resistance in HCC patients.